Increased tumor growth and drug uptake predicts for response to continuous infusion high-dose cytarabine.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001853:Bone Marrow / Q000378:metabolism; D002455:Cell Division; D003561:Cytarabine / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D004247:DNA / Q000096:biosynthesis; D003630:Daunorubicin / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008875:Middle Aged
D003561:Cytarabine; D004247:DNA; D003630:Daunorubicin